136 related articles for article (PubMed ID: 30522952)
1. 5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.
Ding X; Stasi LP; Dai X; Long K; Peng C; Zhao B; Wang H; Sun C; Hu H; Wan Z; Jandu KS; Philps OJ; Chen Y; Wang L; Liu Q; Edge C; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
Bioorg Med Chem Lett; 2019 Jan; 29(2):212-215. PubMed ID: 30522952
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
Ding X; Dai X; Long K; Peng C; Andreotti D; Bamborough P; Eatherton AJ; Edge C; Jandu KS; Nichols PL; Philps OJ; Stasi LP; Wan Z; Xiang JN; Dong K; Dossang P; Ho MH; Li Y; Mensah L; Guan X; Reith AD; Ren F
Bioorg Med Chem Lett; 2017 Sep; 27(17):4034-4038. PubMed ID: 28774425
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
Ding X; Stasi LP; Ho MH; Zhao B; Wang H; Long K; Xu Q; Sang Y; Sun C; Hu H; Yu H; Wan Z; Wang L; Edge C; Liu Q; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
Bioorg Med Chem Lett; 2018 May; 28(9):1615-1620. PubMed ID: 29588215
[TBL] [Abstract][Full Text] [Related]
4. Triazolopyridazine LRRK2 kinase inhibitors.
Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
[TBL] [Abstract][Full Text] [Related]
5. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
6. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
[TBL] [Abstract][Full Text] [Related]
7. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
8. Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Tasegian A; Singh F; Ganley IG; Reith AD; Alessi DR
Biochem J; 2021 Oct; 478(19):3555-3573. PubMed ID: 34515301
[TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of Pyrrolo[2,3-
Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
[TBL] [Abstract][Full Text] [Related]
10. Development and biological evaluation of[
Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P
Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850
[TBL] [Abstract][Full Text] [Related]
11. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
Salado IG; Zaldivar-Diez J; Sebastián-Pérez V; Li L; Geiger L; González S; Campillo NE; Gil C; Morales AV; Perez DI; Martinez A
Eur J Med Chem; 2017 Sep; 138():328-342. PubMed ID: 28688273
[TBL] [Abstract][Full Text] [Related]
12. The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2).
Konstantinidou M; Oun A; Pathak P; Zhang B; Wang Z; Ter Brake F; Dolga AM; Kortholt A; Dömling A
ChemMedChem; 2021 Mar; 16(6):959-965. PubMed ID: 33278061
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
Estrada AA; Liu X; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chan BK; Chen H; Ding X; DiPasquale AG; Dominguez SL; Dotson J; Drummond J; Flagella M; Flynn S; Fuji R; Gill A; Gunzner-Toste J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Lyssikatos JP; Medhurst AD; Moffat JG; Mukund S; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Tran T; Trivedi N; Wang S; Zhang S; Zhang X; Zhao G; Zhu H; Sweeney ZK
J Med Chem; 2012 Nov; 55(22):9416-33. PubMed ID: 22985112
[TBL] [Abstract][Full Text] [Related]
14. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
Göring S; Taymans JM; Baekelandt V; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
[TBL] [Abstract][Full Text] [Related]
16. The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
Kavanagh ME; Doddareddy MR; Kassiou M
Bioorg Med Chem Lett; 2013 Jul; 23(13):3690-6. PubMed ID: 23721803
[TBL] [Abstract][Full Text] [Related]
17. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
[TBL] [Abstract][Full Text] [Related]
18. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
Christensen KV; Smith GP; Williamson DS
Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412
[TBL] [Abstract][Full Text] [Related]
19. Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
Garofalo AW; Bright J; De Lombaert S; Toda AMA; Zobel K; Andreotti D; Beato C; Bernardi S; Budassi F; Caberlotto L; Gao P; Griffante C; Liu X; Mengatto L; Migliore M; Sabbatini FM; Sava A; Serra E; Vincetti P; Zhang M; Carlisle HJ
J Med Chem; 2020 Dec; 63(23):14821-14839. PubMed ID: 33197196
[TBL] [Abstract][Full Text] [Related]
20. Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.
Keylor MH; Gulati A; Kattar SD; Johnson RE; Chau RW; Margrey KA; Ardolino MJ; Zarate C; Poremba KE; Simov V; Morriello GJ; Acton JJ; Pio B; Yan X; Palte RL; McMinn SE; Nogle L; Lesburg CA; Adpressa D; Lin S; Neelamkavil S; Liu P; Su J; Hegde LG; Woodhouse JD; Faltus R; Xiong T; Ciaccio PJ; Piesvaux J; Otte KM; Wood HB; Kennedy ME; Bennett DJ; DiMauro EF; Fell MJ; Fuller PH
J Med Chem; 2022 Jan; 65(1):838-856. PubMed ID: 34967623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
